You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Targeted therapies for ER+/HER2- metastatic breast cancer
|
|---|---|
| Published in |
BMC Medicine, June 2015
|
| DOI | 10.1186/s12916-015-0369-5 |
| Pubmed ID | |
| Authors |
Mutsuko Yamamoto-Ibusuki, Monica Arnedos, Fabrice André |
| Abstract |
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The improvement of our understanding of the cancer genome has identified some promising targets that might be responsible or linked to endocrine resistance, including alterations affecting main signaling pathways like PI3K/Akt/mTOR and CCND1/CDK4-6 as well as the identification of new ESR1 somatic mutations, leading to an array of new targeted therapies that might circumvent or prevent endocrine resistance. In this review, we have summarized the main targeted therapies that are currently being tested in ER+ breast cancer, the rationale behind them, and the new agents and combinational treatments to come. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Ecuador | 1 | <1% |
| United Kingdom | 1 | <1% |
| Egypt | 1 | <1% |
| Denmark | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 116 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 18% |
| Student > Master | 20 | 16% |
| Student > Ph. D. Student | 18 | 15% |
| Student > Bachelor | 17 | 14% |
| Other | 11 | 9% |
| Other | 14 | 11% |
| Unknown | 20 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 23% |
| Biochemistry, Genetics and Molecular Biology | 24 | 20% |
| Agricultural and Biological Sciences | 24 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
| Chemistry | 4 | 3% |
| Other | 8 | 7% |
| Unknown | 24 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 March 2022.
All research outputs
#2,871,195
of 23,881,329 outputs
Outputs from BMC Medicine
#1,753
of 3,613 outputs
Outputs of similar age
#36,997
of 268,639 outputs
Outputs of similar age from BMC Medicine
#34
of 67 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,613 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 44.6. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,639 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.